Combination Foam and Liquid Sclerotherapy for Lower Extremity Reticular and Telangiectatic Veins: A Single-Center Retrospective Study.
| Autor: | Verma KK; Texas Tech University Health Sciences Center, School of Medicine, Lubbock, Texas., Friedmann DP; Westlake Dermatology Clinical Research Center, Westlake Dermatology & Cosmetic Surgery, Austin, Texas. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] [Dermatol Surg] 2024 Nov 01; Vol. 50 (11), pp. 1034-1038. Date of Electronic Publication: 2024 Jun 11. |
| DOI: | 10.1097/DSS.0000000000004273 |
| Abstrakt: | Background: Lower extremity reticular and telangiectatic veins are of common cosmetic concern. Objective: To retrospectively evaluate results of lower extremity sclerotherapy using a combination of foam and liquid sclerosing agents. Methods: A retrospective chart review of sclerotherapy patients at a dermatology practice (January 2014 to April 2023) was performed. Results: Eight hundred and nine patients (775 women and 34 men) with a mean age of 49.6 ± 12.2 (18-84) years underwent a mean 1.4 ± 0.7 (1-7) sessions. Multiple different sclerosing agents were used, with 0.2% sodium tetradecyl sulfate foam/liquid predominating, although 72% glycerin liquid and 0.25% to 0.5% polidocanol foam/liquid were also used. Coagula occurred in 61.0% of patients at 2 weeks and 6.4% at 3 months, whereas postsclerotherapy hyperpigmentation was seen in 5.0% and 19.1% of patients at the same time points. Both were more common after first-round treatment, each with a trend toward decreased frequency with increasing session number. Telangiectatic matting was found in 2.3% of 3-month follow-up patients. Edema, superficial venous thrombophlebitis, migraines, and ulceration were rarely seen. Significant clinical improvement was noted in 72.0% of treatments. Conclusion: This retrospective chart review, the largest to date of its kind, confirms the safety and efficacy of cosmetic lower extremity sclerotherapy with a combination of foam and liquid sclerosing agents. (Copyright © 2024 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|